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advantages of being less invasive, incurring less costs,
and requiring shorter duration of hospital stay. Finally,
I would like to ask the authors whether subgroup anal-
ysis according to the size and number of tumors would
be helpful to clarify the role of surgical resection and
RFA in the treatment of HCC in their large patients.
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hepatocellular carcinoma: ReplyTo the Editor:
We thank Dr. Fujita for his comments on our paper
[1] describing a retrospective comparison of the clinical
eﬀects between surgical resection and percutaneous
ablation, including radiofrequency ablation (RFA), for
hepatocellular carcinoma (HCC). Four major points
were raised in his letter.
First, Dr. Fujita mentions the problem of the short
follow-up period. We agree that this is one of the limita-
tions of our study, as discussed in the paper [1]. We
think that the main reason for the short follow-up peri-
od is the long time needed to collect, collate, and analyze
the clinical data obtained from a Japanese nationwide
survey, because of the large volume of the data. On
the other hand, the drop-out rate would have little inﬂu-
ence on the follow-up period, because the drop-out rates
in the three groups were similar and not signiﬁcant. We
have no information on the reasons for the dropouts.
Second, Dr. Fujita proposed the use of the step-wise
multiple logistic regression analysis, instead of a Cox’s
proportional hazard model. According to the statistician
in our group (Yutaka Matsuyama), a Cox’s propor-
tional hazard model is more appropriate to analyze such
time-to-event data as those presented in our study. Dr.
Fujita has also indicated that the recurrence rate after
RFA was too high as compared to the ‘‘the local recur-
rence rates” reported previously. However, we deter-mined the ‘‘overall recurrence rates” (and not the
‘‘local recurrence rates”) [1], which mainly represent
the frequencies of intrahepatic metastasis and second
primary carcinogenesis. Extrahepatic recurrence is also
included in the overall recurrence rate, although it was
noted in a small proportion of the patients. Thus, the
overall recurrence rate of 55.4% at 2 years after RFA
would be rather compatible with the previously reported
rates, that is, the 2-year cumulative recurrence rate of
43.4% [2] and the 2-year cumulative event-free survival
rate of 37.4% [3], which suggest that the 2-year overall
recurrence rate was about 62.6%.
Third, Dr. Fujita raised a question on the deﬁnition
of local and distant recurrence, and about the eﬀects
of surgery on local recurrence. However, we cannot an-
swer this question, because we do not have any data to
determine the local recurrence rate. It is impossible to
discuss the type of recurrence after surgery and RFA
using the data available to us from this study.
Dr. Fujita expressed his personal opinion following
his third question. He said, ‘‘Therefore, incidence of
appearance of new lesions in cirrhotic liver appears
not to be an adequate measure to evaluate the eﬃcacy
of each therapeutic modality for HCC”. We agree that
the overall survival is the true endpoint to evaluate the
eﬀects of a treatment modality for a malignant disease,
as has been advocated [4]; however, in HCC, the recur-
rence rate, which may include ‘‘incidence of appearance
of new lesions”, should also be evaluated, because the
overall survival can be easily aﬀected by second or sub-
sequent treatments for recurrence.
Dr. Fujita also states, ‘‘it appears that RFA has be-
come an equally eﬀective alternative to surgical resection
for early HCC”. But, what is his opinion based on? We
beg to disagree with this statement, because it is not
based on any concrete data. At least our data [1] do
not lend support to the notion of equality in clinical ef-
fects between surgery and RFA.
Finally, Dr. Fujita has proposed that we conduct a
subgroup analysis according to the size and number of
tumors. We agree with him, because a subgroup analysis
would theoretically be useful in a large volume study like
ours. However, we abandoned this idea, because the
critical limitation of the short follow-up period in our
study can still not be overcome. We shall consider a sub-
group analysis in a future study, using the latest data
being collected now.
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Intraperitoneal application of caﬀeine prevents D-galactosamine-
induced hepatic expression of connective tissue growth factor
(CTGF/CCN2) in the rat
To the Editor:
A recent report from our group published in this Jour-
nal gave evidence that caﬀeine suppresses TGF-b-depen-
dent and -independent Connective Tissue Growth
Factor (CTGF/CCN2) expression in hepatocytes via a
cyclic adenosine monophosphate (cAMP-)-dependent
mechanism that involves upregulation of the nuclear
receptor PPARc and thus sensitization towards the
natural PPARc ligand 15-deoxy-D12,14-Prostaglandin
J 2, as well as enhanced degradation and inhibition
of phosphorylation of the TGF-b eﬀector Smads 2
and 3 [1]. This study ﬁnds clinical parallels in studies
performed by the NIH/NIDDK which have recently
suggested that coﬀee consumption may protect against
cirrhosis, especially against alcoholic cirrhosis [2], and
is of particular interest as it was shown that silencing
of the CTGF gene in vivo almost entirely inhibits ﬁ-
brotic remodeling of livers in mice previously sub-
jected to hepatotoxic agents [3].
Based on these ﬁndings, we aimed at transferring the
results to the in vivo situation by investigating the eﬀect
of intraperitoneal caﬀeine injection on CTGF expression
in the N-acetyl-D-galactosamin-6-sulfate (D-GalN) in-
jured rat livers in vivo and on serum CTGF concentra-
tions. Therefore, 4 adult Sprague–Dawley rats (body
weight 140–145 g) were included in this study. 2 rats
were given a total of 6 intraperitoneal (i.p.) injections
of each 50 mg/kg body weight caﬀeine dissolved in
0.9% NaCl solution every 4 h. One caﬀeine treated rat
as well as one previously untreated rat received an i.p.
injection of D-GalN (500 mg/kg body weight). D-GalN
was applied 1 h after the ﬁrst caﬀeine injection. The con-
trol rat received i.p. injections of 0.9% NaCl instead of
caﬀeine or D-GalN. Rats were killed by abdominal
exsanguination and livers were perfused with 0.9%
NaCl, dehydrated in 70–100% ethanol and eventually
ﬁxed in 4% (w/v) paraformaldehyde buﬀered in PBS,
pH 7.4, and embedded in paraﬃn. Immunohistochemis-
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